Andreas Wollenberg

Vrije Universiteit Brussel — Belgium

Medicine · Health Sciences

79h-index28.1kcitations574works6.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Dermatology and Skin Diseases(389), Allergic Rhinitis and Sensitization(205), Food Allergy and Anaphylaxis Research(126), Asthma and respiratory diseases(118), Urticaria and Related Conditions(88)

Publications572 total

Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis
American Journal of Clinical Dermatology·2025
Perceptions of a Group of Experts on the Integration of Artificial Intelligence in the Management of Atopic Dermatitis
JEADV Clinical Practice·2025Open Access
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema
Dermatology and Therapy·2025· 1 citedOpen Access
Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab
SKIN The Journal of Cutaneous Medicine·2025Open Access
Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment
SKIN The Journal of Cutaneous Medicine·2025Open Access
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
Clinical and Experimental Dermatology·2025Open Access
Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis
Dermatology and Therapy·2025Open Access
Internationale Umfrage zur Behandlungspraktiken bei atopischer Dermatitis bei schwangeren und stillenden Frauen: Perspektiven von Ärzten
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials
British Journal of Dermatology·2025· 4 citedOpen Access
Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Advances in Therapy·2025Open Access
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis
Dermatology and Therapy·2025· 4 citedOpen Access
Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities
Annals of Allergy Asthma & Immunology·2025Open Access
International survey of treatment practices for atopic dermatitis in pregnant and breastfeeding women: Physician perspectives
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
European Guideline (<scp>EuroGuiDerm</scp>) on atopic eczema: Living update
Journal of the European Academy of Dermatology and Venereology·2025· 23 citedOpen Access
Correction to: Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
American Journal of Clinical Dermatology·2025· 1 citedOpen Access
Basic Emollients for Xerosis Cutis in Atopic Dermatitis: A Review of Clinical Studies
International Journal of Dermatology·2025· 11 citedOpen Access
Basic Emollients for the Management of Xerosis Cutis: Biophysical Properties, Clinical Evidence, and Practical Considerations
International Journal of Dermatology·2025Open Access
L’upadacitinib augmente la proportion de patients atteints de dermatite atopique modérée à sévère atteignant l’activité minimale de la maladie : résultats des études de phase 3 (measure up 1 et measure up 2)
Revue française d'allergologie·2025
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
American Journal of Clinical Dermatology·2025· 13 citedOpen Access
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
American Journal of Clinical Dermatology·2025· 11 cited
page 1 of 29Next →

Frequent Co-authors

Thomas Bieber(18), Mette Deleuran(14), Johannes Ring(13), Uwe Gieler(10), Alain Taı̈eb(10), Thomas Werfel(10), Dagmar Simon(10), Michael J. Cork(9), S. Barbarot(8), Ulf Darsow(8), Eric L. Simpson(7), Emma Guttman‐Yassky(7), Jacek C. Szepietowski(7), A. Fink‐Wagner(6), Giampiero Girolomoni(6), Zsuzsanna Szalai(6), A. P. Oranje(6), Stefania Seidenari(6), Carsten Flohr(6), Marjolein de Bruin‐Weller(6)